REVIEW

Gut Microbiota and Brain Function: An Evolving Field in Neuroscience

Jane A Foster, PhD; Mark Lyte, PhD; Emeran Meyer, MD; and John F Cryan, PhD

Department of Psychiatry & Behavioral Neurosciences, McMaster University; and Brain-Body Institute, St. Joseph’s Healthcare, Hamilton, ON, Canada (Dr Foster); Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA (Dr Lyte); Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA (Dr Meyer); Department of Anatomy & Neuroscience and APC Microbiome Institute, University College Cork, Ireland (Dr Cryan).

Correspondence: Jane A Foster, PhD, Department of Psychiatry & Behavioral Neurosciences, St. Joseph’s Healthcare, 50 Charlton Ave. E., T3308, Hamilton, ON L8N 4A6 (jfoster@mcmaster.ca).

Abstract

There is a growing appreciation of the importance of gut microbiota to health and disease. This has been driven by advances in sequencing technology and recent findings demonstrating the important role of microbiota in common health disorders such as obesity. Moreover, the potential role of gut microbiota in influencing brain function, behavior, and mental health has attracted the attention of neuroscientists and psychiatrists. At the 29th International College of Neuropsychopharmacology (CINP) World Congress held in Vancouver, Canada, in June 2014, a group of experts presented the symposium, “Gut microbiota and brain function: Relevance to psychiatric disorders” to review the latest findings in how gut microbiota may play a role in brain function, behavior, and disease. The symposium covered a broad range of topics, including gut microbiota and neuroendocrine function, the influence of gut microbiota on behavior, probiotics as regulators of brain and behavior, and imaging the gut-brain axis in humans. This report provides an overview of these presentations.

Keywords: Behavior, brain imaging, immune, neuroendocrine, MRI, probiotic

Microbiota and Behavior

The role of the microbiome in the determination of behavior and cognition is increasingly being recognized (Cryan and Dinan, 2012; Collins et al., 2013; Foster and McVey Neufeld, 2013; Lyte, 2013). In fact, the development of the brain itself in the growing infant has been shown to be influenced by the microbiome (Douglas-Escobar et al., 2013). As such, the communication of gut microbiota with the brain, through what is referred to as the microbiota-gut-brain axis, represents a new biological axis by which novel diet-based therapies can be designed to influence brain function and behavior. Early studies in animals first demonstrated that the introduction of a single, unique bacterium in the gut resulted in the development of anxiety-like behavior in mice, with concomitant activation of neuronal regions in the brain that were dependent on information received from the gut via the vagus nerve (Goehler et al., 2005). Later studies showed that the transplantation of the fecal microbiome from one mouse strain displaying a phenotypic set of behaviors to another strain resulted in the recipient strain exhibiting the behavioral phenotype of the donor (Bercik et al., 2011a; Collins et al., 2013). Ongoing research continues to demonstrate in humans that the composition of the microbiota has a dramatic influence on the behavior of the individual. For example, the composition of the mucosal microbiota of cirrhotic patients was linked to poor cognition (Bajaj et al., 2012).
Much of our understanding related to how microbiota may influence behavior comes from animal studies that manipulate the composition and diversity of gut microbiota. The germ-free (GF) mouse has been a useful animal model to help determine the domains of behavior that are influenced by microbiota. The GF mouse model was established in 1957, where GF mice are raised in sterile/gnotobiotic environments and have no commensal bacteria (Gustafsson et al., 1957; Gustafsson, 1959). Both the mucosal and the systemic immune systems of GF mice are immature, with reduced numbers of B lymphocytes and T lymphocytes (Macpherson and Harris, 2004). A landmark study showed that GF mice had exaggerated stress-reactivity in response to restraint stress, revealed by increased plasma corticosterone and plasma adrenocorticotropic hormone levels compared to specific pathogen-free (SPF) mice (Sudo et al., 2004). This publication was really the stimulus for neuroscientists to consider the GF mouse model (Sudo et al., 2004). The question arose as to whether or not GF mice would show an altered behavioral phenotype. Several research groups have examined behavior in germ-free mice; these studies are summarized in Table 1. Across these studies, some common findings have emerged. First, all GF mice showed reduced anxiety-like behavior, compared to conventionally-housed mice, in the elevated plus maze (EPM) and light/dark test (Heijtz et al., 2011; Neufeld et al., 2011b; Clarke et al., 2013). Second of all, reconstruction of GF mice with strain-matched microbiota early in life is able to normalize many of the behaviors (Heijtz et al., 2011; Clarke et al., 2013), whereas reconstitution of GF mice in adulthood was not able to change the reduced trait anxiety–like phenotype observed in the EPM (Neufeld et al., 2011a). Interestingly, one can argue that the behavioral phenotype is linked directly to the microbiota, as the transfer of SPF Balb/C microbiota to GF Swiss Webster (SW) mice reduced exploratory behavior compared to normal SW mice, while transfer of SPF SW microbiota to GF Balb/C mice increased exploratory behavior compared to normal Balb/C mice (Bercik et al., 2011a). In stress-sensitive F344 rats, GF rats showed reduced social interaction, reduced center entries in the open field (OF), and increased time spent in the corners of the OF (Crumeyrolle-Arias et al., 2014). These observations are opposite the exploratory and anxiety-like differences mentioned above in several non–stress sensitive strains of mice; however, these observations parallel social behavior deficits that have been reported in GF SW mice (Desbonnet et al., 2013). Together, the above studies identify both exploratory and anxiety-like behaviors and social behavior as domains that are influenced by microbiota. The suggestion that strains modulate the influence of microbiota is important to consider and was addressed in a recent paper using stress-sensitive Balb/C mice. Researchers compared GF Balb/C mice to the offspring of conventionalized GF Balb/C mice (EX-GF) and showed less anxiety-like behavior in EX-GF mice in both the OF and in the marble burying test (Nishino et al., 2013). Monoassociation with Clostridium cocccoides also reduced anxiety-like behavior, whereas monoassociation with Bifido infantis showed reduced activity in the OF and no changes in anxiety-like behavior compared to GF mice (Nishino et al., 2013). Understanding which microbiota specifically influence behavior is a central theme of ongoing research in this area.

Probiotic Studies in Animals

Several groups have examined the effect of probiotic administration on behavior. Initial reports in rats showed no effect of probiotic administration to healthy rats. First, administration of Lactobacillus salivarius, B. infantis, or B. breve to healthy Sprague-Dawley or Wistar rats had no effect on open field behavior (McKernan et al., 2010). Second, administration of B. infantis to healthy Sprague-Dawley rats showed no effect on depressive-like behavior in the forced swim test (FST; Desbonnet et al., 2008); however, 45 days of treatment with B. infantis in rats exposed to early-life maternal separation normalized stress-induced depressive-like behavior in the FST (Desbonnet et al., 2010). Similarly, probiotic treatment has been shown to be beneficial in animal models of infection and colitis (Bercik et al., 2010, 2011b). Specifically, administration of L. rhamnosus for 10 days normalized anxiety-like behavior induced by the parasite Trichuris muris (Bercik et al., 2011b) and administration of B. longum for 14 days normalized anxiety-like behavior induced by dextran sodium sulphate colitis (Bercik et al., 2011b). Interestingly, a few studies have reported a change in behavior when probiotics are administered to healthy rodents. For example, 28-day administration of L. rhamnosus to Balb/C mice resulted in reduced anxiety-like behavior in the EPM and reduced depressive-like behavior in the FST (Bravo et al., 2011). It has also been shown that B. Breve and B. Longum both significantly reduced anxiety-related behaviors, albeit with different profiles (Savignac et al., 2014), and the latter strain, but not former, enhanced cognitive function in healthy Balb/C mice (Savignac et al., 2015). Also, 14-day administration of the combination of L. helveticus and B. longum reduced anxiety-like behavior in the defensive marble burying test in Wistar rats (Messaudi et al., 2011a). Interestingly, administration of this combination of probiotics to healthy human subjects showed a beneficial effect on anxiety and depression measures (Messaudi et al., 2011b). Other combinations of probiotics have been shown to reduce a sad mood triggered by a psychological stimulus (Steenbergen et al., 2015) and to reduce depression anxiety and stress scales whilst modulating the hypothalamic pituitary adrenal (HPA) axis in petrochemical workers (Mohammadi et al., 2015).

Microbiota, Immune Signaling, and the Brain

While several gut–brain pathways are suggested to play a role in microbiota-to-brain signaling (Cryan and Dinan, 2012; Foster and McVey Neufeld, 2013), this CINP symposium presented key findings related to the role of immune signaling in behavior. Researchers in psychiatry and behavioral neuroscience are increasingly recognizing the importance of the adaptive immune system in behavior. Recombinase-activating gene-1 (RAG-1) is a component of the adaptive immune recombination system (Chun et al., 1991). Deletion of RAG-1 results in the ability of lymphocytes to execute VDJ recombination, a mechanism of genetic recombination that rearranges variable (V), joining (J), and diversity (D) gene segments to create diversity in the variable chain of the T cell receptor. This deletion generates mice that lack mature T and B cells, thus silencing the adaptive immune system (Mombaerts et al., 1992). RAG1−/− mice (Cushman et al., 2003) show reduced anxiety-like behavior. Mice lacking both μ2 microglobulin and transporters associated with the antigen processing genes (μ2M−/−TAP−/−), resulting in the loss of functional class I major histocompatibility complex (MHC) molecules and depleted CD8 T cells (Sankar et al., 2012), show no differences in time spent in the open arm of the EPM; however, they showed increased risk assessment behaviors (Sankar et al., 2012). Mice lacking T cell receptor β and δ chains (TCRδ−/−Tγ−/−) and deficient of T cells showed reduced anxiety-like behavior in the EPM, light/dark test, and OF, whereas these behavioral differences are not observed in B cell deficient mice (Rilett et al., 2015). In
**Table 1.** Behavioral outcomes in germ-free mice

| Behavioral Test | Sex/Strain/Species | Outcome | Ref |
|-----------------|-------------------|---------|-----|
| GF, Conventionalized (8 w) GF mice | EPM | F SW mice | • GF mice spent more time in open arms, showed increased # of open arm entries, no activity difference | (Neufeld et al., 2011a, 2011b) |
| GF, SPF Conventionalized (dams prior to mating) | EPM Light/Dark Test | M NMRI | • GF mice spent more time in open arms of EPM and more time in light chamber of L/D test | (Heijtz et al., 2011) |
| GF SW colonized with Balb/C or SW SPF microbiota; GF Balb/C colonized with Balb/C or SW SPF microbiota | Light/Dark Test; step-down | M Balb/C and SW mice | • SPF Balb/C mice exposed to 7 days of antibiotic cocktail spent more time in the light chamber of the light/dark test and showed increased transitions; in addition, the stepped down faster from elevated platform | (Bercik et al., 2011a) |
| GF, Conventionalized (P21) GF mice (GFC) | Light/Dark Test | M and F SW mice | • GF mice transitioned more between the light and dark chamber in the light/dark test | (Clarke et al., 2013) |
| GF Conventionalized (P21) GF mice (GFC) | 3 chamber social behavior; social transmission of food preference | M and F SW mice | • GF mice show reduced sociability which normalized in GF mice | (Desbonnet et al., 2013) |
| Expt 1 – GF, GF 24h in SPF conditions | OF, marble burying test | M Balb/C mice | • Expt 1 - GF mice retested after 24h exposure to normal housing conditions showed reduced number of marbles buried and reduced time spent in the periphery of the OF; no differences seen in GF mice retested in GF conditions | (Nishino et al., 2013) |
| Expt 2 – GF, EX-GF (offspring of conventionalized GF mice), Bi – GF monoassociated with Bifidobacterium infantis, Bc – GF monoassociated with Clostridium coccoides | | | • Expt 2 – reduced number of marbles buried at 10 and 16 w of age and reduced time spent in the periphery of the OF in EX-GF mice compared to GF mice at 7, 10 and 16 w of age, also reduced distance travelled in OF across time points | |
| GF, SPF | Social interaction; OF | M F344 stress-sensitive rats | • GF rats showed less sniffing behavior during the first 2 min of the social interaction test | (Cruseyrolle-Arias et al., 2014) |
| | | | • GF rats showed reduced center entries, increased latency to first move, and increased time spent in the corners of the open field (6 min test) | |

EPM, Elevated Plus Maze; EX-GF, the offspring of conventionalized GF Balb/C mice; F, female; GF, germ-free; M, male; OF, open field; SPF, specific pathogen free; SW, Swiss Webster
the study with β2M−/− TAP−/− mice we observed a loss of sexual dimorphism in activity, exploratory, and anxiety-like behaviors compared to B6 mice (Sankar et al., 2012). This was also observed in TCRβ−/− β−/− mice (Riett et al., 2015). Considering the evidence of sexual dimorphisms in immune functioning (Weinstein et al., 1984; Da Silva, 1999; De Leon-Nava et al., 2009), it is seems reasonable and necessary to further examine a role for immune phenotype in sex differences in behavior.

Microbiota Produce Neurochemicals that Affect the Brain

In many of the studies that have addressed mechanisms by which microbes can influence behavior, the conclusions are that such mechanisms involve the immune system to some degree, as noted in the above section. This is not surprising given that such studies often involve the administration of a microorganism in a manner that nearly guarantees an immune system response. However, mechanisms by which microbiota-gut-brain communication can occur that are non-immune mediated are becoming an area of growing research interest (Lyte and Cryan, 2014a).

The ability of bacteria to produce and recognize neurochemicals (Lyte, 2013) provides a mechanistic basis with which to examine the ability of the microbiota to influence the microbiome-gut-brain axis. The recognition that prokaryotic, as well as eukaryotic, microorganisms produce, as well as possess, receptors for a wide range of neuroendocrine hormones has in fact been known for decades (for reviews see Lenard, 1992, and Roshchina, 2010). The range of neurohormones that are found in microorganisms is extremely diverse, ranging from somatostatin to acetylcholine to progesterone. Critically, microorganisms which inhabit the gastrointestinal tract are capable of producing neurochemicals that can bind to host receptors (intra- and extra-intestinal) in sufficient quantities to effect neurophysiologically changes in the host. Asano et al. (2012) established that the microbiota is capable of the in situ production of the biologically active neuroendocrine hormones dopamine and norepinephrine, in quantities large enough to affect host neurophysiology.

Production and recognition of neurochemicals that are more commonly associated with mammals by prokaryotic and eukaryotic microorganisms has led to a new understanding of an evolutionary-based mechanism by which microbes can influence host behavior and vice versa: namely, microbial endocrinology (Lyte, 2014a, 2014b; Lyte and Cryan, 2014b). Microbial endocrinology represents the intersection of the fields of microbiology and neuroendocrinology and had its beginnings in the demonstration that neurochemicals produced by the host during periods of stress, such as the biogenic amine norepinephrine, could dramatically increase the growth of bacteria both in vitro and in vivo (for review see Lyte, 2010).

Given that bacteria are prolific producers of neuroendocrine hormones, as well as other neuroactive compounds (Holzer and Farzi, 2014), it would seem reasonable to conclude that such bacterial production of neuroactive compounds within the gut lumen could influence either host-specific neural receptors within the gut or extra-intestinal neuronal sites following luminal uptake into the portal circulation. There are a number of reports that provide support that neurochemical production by bacteria within the gut can influence behavior in both human and animal model systems (Bravo et al., 2011; Messaoudi et al., 2011a; Collins et al., 2013). Most often, these reports employ probiotic bacteria, such as Lactobacillus or Bifidobacterium: many of the species belonging to these two genera are prolific producers of neurochemicals for which well-defined neural mechanisms are known and by which behavior may be modulated. Of particular interest, Bravo and colleagues (2011) observed reduced anxiety-like and depressive-like behavior in mice fed the probiotic strain L. rhamnosus (JB-1). Following probiotic administration, they were able to demonstrate changes in the levels of GABA mRNA in those brain regions associated with the specific behavior (Bravo et al., 2011). Although they did not quantify the amount of GABA produced by the administered L. rhamnosus (JB-1) strain, the demonstration of a mechanism such as that mediated via central GABA receptor expression provides evidence that the ability of bacteria to influence behavior can occur through a neurochemical-mediated route.

And as to whether bacteria are capable of producing enough quantities of neurochemicals to affect behavior, a recent study that employed the GABA-producing Lactobacillus brevis FPA 3709 amply demonstrates that ability. In this functional food study, L. brevis was used to enrich black soybean milk with GABA, which was then fed to rats subjected to the FST (Ko et al., 2013). The FST, in which animals are placed in a water-containing glass cylinder and the duration of immobility before the animals begin to swim is measured, is a well-recognized test of depressive-like behavior. In this study, the GABA-enriched soybean milk significantly reduced the immobility time before the rats began to swim and was as effective as the selective serotonin reuptake inhibitor fluoxetine as an antidepressant (Ko et al., 2013). The use and design of probiotics based on a microbial endocrinology-based approach has also been proposed (Lyte, 2011).

Microbiota and Brain Imaging

Although much of the progress in understanding how the microbiota-gut-brain axis influences brain function and behavior has been in preclinical studies, work is now moving forward in human populations. Alterations in the microbiota-gut-brain axis have been implicated in brain-gut disorders such as functional gastrointestinal (GI) disorders (Mayer and Tillisch, 2011), inflammatory bowel diseases (Mayer et al., 2014), obesity, and metabolic syndrome (Yau et al., 2012). In addition, microbiota are also implicated in non-GI brain disorders, including anxiety and depression, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and autism (Cryan and Dinan, 2012; Foster and McVey Neufeld, 2013; Naseribafrouei et al., 2014; Jiang et al., 2015; Mayer et al., 2015; Scheperjans et al., 2015). Results to date point to changes in microbiota composition and diversity in patient populations compared to healthy individuals: however, few studies have made direct links between gut microbiota and brain function. One approach to study gut-brain interactions in human populations is to combine manipulations of the gut microbiota, but did modulate some metabolic pathways involved in polysaccharide degradation, including amino acid metabolism (McNulty et al., 2011). Interestingly, consumption of
the test product containing probiotics for 4 weeks was associated with reduced engagement of an extensive brain network in response to an emotion recognition task (Tillisch et al., 2013). The widely distributed brain network was increased in the no treatment group, not different in the individual who consumed the control product, and decreased in those who consumed the probiotic mixture (Tillisch et al., 2013). Ongoing work in the field of brain imaging includes an approach to connect gut microbial ecology (Saulnier et al., 2011) with large-scale brain networks (Irmitia and Van Horn, 2013). Such approaches will aid in our ability to determine how the microbiome influences brain function and to potentially identify multiple mediators of the gut-brain axis.

Experimental Challenges Ahead

The past 5 years have seen an amazing increase in our knowledge of how bacteria signal to the brain and the implications this has for psychiatry. There are still many open questions, however. Firstly, the mechanisms of how the microbiota signals to the brain are only slowly being unraveled. The studies that have been performed to date have not yet conclusively demonstrated that a microbial endocrinology-based mechanism can account for the observed ability of the gut microbiota to influence behavior. We are at the very early stages of research, which will need to employ experimental rigor that must be employed to unequivocally demonstrate that it is the actual production of a neurochemical in vivo by a specific microorganism, and not a non-neurochemical aspect of the microorganism, such as a cell wall component interacting with immune cells in the gut, that is responsible for a specific change in behavior. Further, receptor-specific binding within the gut or extra-intestinal site must be demonstrated for the specific neurochemical produced by the microorganism. Recently, a step-by-step experimental approach was introduced to guide the experimental design for probiotics that seek to examine such microbial endocrinology-based mechanisms (Lyte, 2011). Such experiments are currently underway in a number of laboratories, and will provide a definitive answer.

Secondly, the individual components of bacteria that are mediating their effects need to be disentangled. As the field continues to consider composition and diversity of the microbiota in natural, clinical, and experimental settings, the evolving field of metabolomics is advancing and assisting in our ability to better understand the signaling cascades and roles of bacterial products.

Thirdly, as most of the studies to date have been in rodents, further human studies are needed to determine if bacteria-based interventions can indeed have a positive effect on mental health, a so-called psychobiotic effect (Dinan et al., 2013). Although some preliminary studies have focused on the altered composition of the microbiota in depression and autism, the time is now ripe for a comprehensive analysis of the microbiota in other disorders, including schizophrenia, anxiety, drug addiction, and eating disorders (Bach-Mizrachi et al., 2006; Dinan et al., 2014; Leclercq et al., 2014; Burokas et al., 2015; Fond et al., 2015; Nemani et al., 2015), followed by mechanistic studies that will determine if such changes have any causal relationship to psychiatric symptomatology.

Acknowledgments

None.

Statement of Interest

None.

References

Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N (2012) Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol 303:G1288–1295.

Bach-Mizrachi H, Underwood MD, Kassir SA, Bakalian MJ, Sibille E, Tamir H, Mann JJ, Arango V (2006) Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. Neuropsychopharmacology 31:814–824.

Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteiith P, Noble NA, Sikaaroodi M, Gillevet PM (2012) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303:G675–685.

Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA, Lu J, Khan WI, Corthesy-Theulaz I, Cherbut C, Bergonzelli GE, Collins SM (2010) Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology 139:2102–2112.

Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM (2011a) The intestinal microbiota affect central levels of brain-derived neurotrophic factor and behavior in mice. Gastroenterology 141:599–609.

Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, Deng Y, Blennerhassett PA, Fahnstock M, Moine D, Berger B, Huizinga JD, Kuzne W, McLean PG, Bergonzelli GE, Collins SM, Verdu EF (2011b) The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil 23:1132–1139.

Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF (2011) Ingestion of Lactobacillus rhamnosus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 108:16050–16055.

Burokas A, Moloney RD, Dinan TG, Cryan JF (2015) Microbiota regulation of the Mammalian gut-brain axis. Adv Appl Microbiol 91:1–62.

Chun JJ, Schatz DG, Gettinger MA, Jaenisch R, Baltimore D (1991) The recombination activating gene-1 (RAG-1) transcript is present in the murine central nervous system. Cell 64:189–200.

Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF (2013) The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry 18:666–673.

Collins SM, Kassam Z, Bercik P (2013) The adaptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Curr Opin Microbiol 16:240–245.

Crumeyrolle-Arias M, Jaglin M, Brunau N, Vancassol S, Cardona A, Dauge V, Naudon L, Rabot S (2014) Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. Psychoneuroendocrinology 42:207–217.
Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behavior. Nat Rev Neurosci 13:701–712.

Cushman J, Lo J, Huang Z, Wasserfall C, Petitto JM (2003) Neuroendocrine changes resulting from recombinase activation gene 1 deletion. Clin Diagn Lab Immunol 10:13–18.

Da Silva JA (1999) Sex hormones and glucocorticoids: interactions with the immune system. Ann NY Acad Sci 876:102–117; discussion 117–108.

De Leon-Nava MA, Nava K, Soldevila G, Lopez-Griego L, Chavez-Rios JR, Vargas-Villavicencio JA, Morales-Montor J (2009) Immune sexual dimorphism: effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation. J Steroid Biochem Mol Biol 113:57–64.

Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG (2008) The probiotic Bifidobacterium infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res 43:164–174.

Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG (2010) Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 170:1179–1188.

Desbonnet L, Clarke G, Shanahan F, Dinan TG, Cryan JF (2013) Microbiota is essential for social development in the mouse. Mol Psychiatry 19:146–148.

Dinan TG, Stanton C, Cryan JF (2013) Psychobiotics: a novel class of psychotropic. Biol Psychiatry 74:720–726.

Dinan TG, Borre YE, Cryan JF (2014) Genomics of schizophrenia: time to consider the gut microbiome? Mol Psychiatry 19:1252–1257.

Douglas-Escobar M, Elliott E, Neu J (2013) Effect of intestinal microbial ecology on the developing brain. JAMA Pediatr 167:374–379.

Fond G, Boukouaci W, Chevalier G, Regnault A, Eberl G, Hamdani N, Dickerson F, Maçgregor A, Boyer L, Dargel A, Oliveira J, Tamouza R, Leboyer M (2015) The “psychomicrobial”- Targeting microbiota in major psychiatric disorders: a systematic review. Pathol Biol (Paris) 63:35–42.

Foster JA, McVey Neufeld KA (2013) Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neu rosci 36:305–312.

Goehler LE, Gaykema RP, Opitz N, Reddaway R, Badr N, Lyte M (2005) Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni. Brain Behav Immun 19:334–344.

Gustafsson B, Kahaon G, Rosengren E (1957) Biogenesis of histamine studied by its distribution and urinary excretion in germ free reared and not germ free rats fed a histamine free diet. Acta Physiol Scand 41:217–224.

Gustafsson BE (1959) Lightweight stainless steel systems for rearing germfree animals. Ann NY Acad Sci 78:17–28.

Heijtz RD, Wang S, Anuar Y, Qian Y, Bjorkholm B, Samuelsson A, Hibberd ML, Forsberg H, Pettersson S (2011) Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 108:3047–3052.

Holzer P, Farzi A (2014) Neuropeptides and the microbiota-gut-brain axis. In: Microbial endocrinology: the microbiota-gut-brain axis in health and disease (Lyte M, Cryan JF, eds), pp. 195–220. New York: Springer-Verlag.

Irini A, Van Horn JD (2013) The structural, connectomic and network covariance of the human brain. Neuroimage 66:489–499.

Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L, Ruan B (2015) Altered fecal microbiota composi- tion in patients with major depressive disorder. Brain Behav Immun. doi:10.1016/j.bbi.2015.03.016.

Ko CY, Lin HT, Tsai GJ (2013) Gamma-aminobutyric acid production in black soybean milk by Lactobacillus brevis FFA 3709 and the antidepressant effect of the fermented product on a forced swimming rat model. Process Biochem 48:559–568.

Leclercq S, Matamoros S, Cani PD, Neirynck AM, Jamar F, Starkel P, Windey K, Tremaroli V, Sackfeld F, Verbeke K, de Timary P, Delzenne NM (2014) Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA 111:E4485–4493.

Lenard J (1992) Mammalian hormones in microbial cells. Trends Microbiol 6:374–379.

Lyte M (2010) Microbial endocrinology: a personal journey. In: Microbial endocrinology: interkingdom signaling in infectious disease and health (Lyte M, Freestone PPE, eds), pp 1–16. New York: Springer.

Lyte M (2011) Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design and use of probiotics. Bioessays 33:574–581.

Lyte M (2013) Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. PLOS Pathog 9:e1003726.

Lyte M (2014a) Microbial endocrinology and the microbiota-gut-brain axis. Adv Exp Med Biol 817:3–24.

Lyte M (2014b) Microbial endocrinology: Host-microbiota neuroendocrine interactions influencing brain and behavior. Gut Microbes 5:381–389.

Lyte M, Cryan JF (2014a) Dealing with ability of the microbiota to influence the brain, and ultimately cognition and behavioral. Adv Exp Med Biol 817:ix–xi.

Lyte M, Cryan JF (2014b) Microbial endocrinology: the microbiota-gut-brain axis in health and disease. New York: Springer.

Macpherson AJ, Harris NL (2004) Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 4:478–485.

Mayer EA, Tillisch K (2011) The brain-gut axis in abdominal pain syndromes. Annu Rev Med 62:381–396.

Mayer EA, Savidge T, Shulman RJ (2014) Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 146:1500–1512.

Mayer EA, Tillisch K, Gupta A (2015) Gut-brain axis and the microbiota. J Clin Invest 125:926–938.

McKernan DP, Fitzgerald P, Dinan TG, Cryan JF (2010) The probiotic Bifidobacterium infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res 43:164–174.

McNulty NP, Yatsunenko T, Hsiao A, Faith JJ, Muegge BD, Good- man AL, Henrissat B, Oozeer R, Cools-Portier S, Gobert G, Chervaux C, Knights D, Lozupone CA, Knight R, Duncan AE, Bain JR, Muehlbauer MJ, Newgard CB, Heath AC, Gordon JI (2011) The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med 3:106ra106.

Messaoudi M, Lalonde R, Viole N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M, Cazaubiel JM (2011a) Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 105:755–764.

Messaoudi M, Viole N, Bisson JF, Desor D, Javelot H, Rougeot C (2011b) Beneficial psychological effects of a probiotic formu-
lation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes 2:256–261.

Mohammadi AA, Jazayeri S, Khosravi-Darani K, Solati Z, Mohammadpour N, Asemi Z, Adab Z, Djalali M, Tehrani-Doost M, Hosseini M, Eghtesadi S (2015) The effects of probiotics on mental health and hypothalamic-pituitary-adrenal axis: a randomized, double-blind, placebo-controlled trial in petrochemical workers. Nutr Neurosci. Epub 16 Apr 2015.

Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869–877.

Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linlokken A, Wilson R, Rudi K (2014) Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil 26:1155–1162.

Nemani K, Hosseini Ghomi R, McCormick B, Fan X (2015) Schizophrenia and the gut-brain axis. Prog Neuropsychopharmacol Biol Psychiatry 56:155–160.

Neufeld KM, Kang N, Bienenstock J, Foster JA (2011a) Effects of intestinal microbiota on anxiety-like behavior. Commun Integr Biol 4:492–494.

Neufeld KM, Kang N, Bienenstock J, Foster JA (2011b) Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 23:255–264.

Nishino R, Mikami K, Takahashi H, Tomonaga S, Furuse M, Hiramoto T, Aiba Y, Koga Y, Sudo N (2013) Commensal microbiota modulate murine behaviors in a strictly contamination-free environment confirmed by culture-based methods. Neurogastroenterol Motil 25:521–528.

Rilett KC, Friedel M, Ellegood J, MacKenzie RN, Lerch JP, Foster JA (2015) Loss of T cells influences sex differences in behavior and brain structure. Brain Behav Immun 46:249–260.

Roshchina VV (2010) Evolutionary considerations of neurotransmitters in microbial, plant and animal cells. In: Microbial endocrinology: interkingdom signaling in infectious disease and health (Lyte M, Freestone PP, eds), pp 17–52. New York: Springer.

Sankar A, Mackenzie RN, Foster JA (2012) Loss of class I MHC function alters behavior and stress reactivity. J Neuroimmunol 244:8–15.

Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J (2011) Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141:1782–1791.

Savignac HM, Kiely B, Dinan TG, Cryan JF (2014) Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. Neurogastroenterol Motil 26:1615–1627.

Savignac HM, Tramullas M, Kiely B, Dinan TG, Cryan JF (2015) Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behav Brain Res 287:59–72.

Scheperjans F, Aho V, Pereira PA, Koskinnen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P (2015) Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 30:350–358.

Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS (2015) A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav Immun 48:258–264.

Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y (2004) Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 558:263–275.

Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, Mayer EA (2013) Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144:1394–1401.

Weinstein Y, Ran S, Segal S (1984) Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J Immunol 132:656–661.

Yau PL, Castro MG, Tagani A, Tsui WH, Convit A (2012) Obesity and metabolic syndrome and functional and structural brain impairments in adolescence. Pediatr 130:e856–864.